Clinical Trial Update: Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pimecrolimus 1% cream in adults with mild to moderate chronic hand dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hand Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Chronic Hand Dermatitis | Phase 3 | Status: COMPLETED